Metastatic osteosarcoma: a challenging multidisciplinary treatment

References

• Picci P, Manfrin M, Fabbri N, et al. Classic osteosarcoma. In: Picci P, Manfrini M, Fabbri N, editors. Atlas of muskuloskeletal tumors and tumorlike lesions. Cham, Switzerland: Springer International Publishing; 2014. p. 147–152.
   Google Scholar
• ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014;25(3):113–123.
   Web of Science ®Google Scholar
• Geller D, Gorlick R. Osteosarcoma: a review of diagnosis, managment and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–718.
   PubMedGoogle Scholar
• Stiller CA, Bielack SS, Jundt G, et al. Bone tumors in European children and adolescents, 1978-1997. Report from the automated childhood cancer infromation system project. Eur J Cancer. 2006;42:2124–2135.
   PubMed Web of Science ®Google Scholar
• Gatta G, Botta L, Rossi S, et al. Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15(1):35–47.
   PubMed Web of Science ®Google Scholar
• Cotterill SJ, Wright CM, Pearce MS, et al. Stature of young people with malignant bone tumors. Pediatric Blood Cancer. 2004;42(1):59–63.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–790.
   PubMed Web of Science ®Google Scholar
• Gorlick R. Current concept on the molecular biology of osteosarcoma. Cancer Treat Res. 2009;152:63–84.
   PubMedGoogle Scholar
• Entz-Werle N, Schneider A, Kalifa C, et al. Genetic alterations in primary osteosarcoma. From 54 children and adolescents by target allelotyping. Br J Cancer. 2003;88:1925–1931.
   PubMed Web of Science ®Google Scholar
• Marina N, Gebhardt M, Teot L, et al. Biology and therapeutic advances for paediatric osteosarcoma. Oncologist. 2004;9:422–441.
   PubMed Web of Science ®Google Scholar
• Chou AJ, Geller D, Gorlick R. Therapy for osteosarcoma: where do we go from here? Pediatr Drugs. 2008;10:315–327.
   PubMedGoogle Scholar
• Bacci G, Longhi A, Bertoni F, et al. Bone metastases in osteosarcoma patients treated with adjuvant or neoadjuvant chemotherapy: The Rizzoli experience in 52 patients. Acta Orthop. 2006;77:938–943.
   PubMed Web of Science ®Google Scholar
• Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res. 2010;152:3–13.
   Google Scholar
• Carrle D, Bielack S. Osteosarcoma lung metastases detection and principles of multimodal therapy. Cancer Treat Res. 2009;152:165–184.
   PubMedGoogle Scholar
• Luetke A, Meyers P, Lewis I, et al. Osteosarcoma treatment – Where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–532.
   PubMed Web of Science ®Google Scholar
• Ta HT, Dass CR, Choong PF, et al. Osteosarcoma treatment. State of the art. Cancer Metastasis Rev. 2009;28:247–263.
   PubMed Web of Science ®Google Scholar
• Kempf-Bielack B, Bielack SS, Juergens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group (COSS). J Clin Oncol. 2005;23:559–568.
   PubMed Web of Science ®Google Scholar
• Bruland OS, Phil A. On the current management of osteosarcoma. A critical evaluation and proposal for a modified treatment strategy. Eur J Cancer. 1997;33:1725–1731.
   PubMed Web of Science ®Google Scholar
• Lamourex F, Trichet V, Chipoy C, et al. Recent advances in the management of osteosarcoma and forthcoming therapeutic strategies. Expert Rev Anticancer Ther. 2007;7:169–181.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Palmerini E. Adjuvant and neoadjuvant combination chemotherapy for osteogenic osteosarcoma. Curr Opin Oncol. 2007;19:341–346.
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Versari M, et al. Prognostic factors for osteosarcoma of the extremity treated with chemotherapy: 15-year experience in 789 patients treated at single institution. Cancer. 2006;106:1154–1161.
   PubMed Web of Science ®Google Scholar
• Rosen G, Caparros B, Huvos AG, et al. Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on response of the primary tumor to preoperative chemotherapy. Cancer. 1982;49:1221–1230.
   PubMed Web of Science ®Google Scholar
• Picci P, Bacci G, Campanacci M, et al. Histological evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer. 1985;56:1515–1521.
   PubMed Web of Science ®Google Scholar
• Winkler K, Beron G, Delling G, et al. Neoadjuvant chemotherapy of osteosarcoma: results of a randomized cooperative trial (COSS-82) with salvage chemotherapy based on histological tumor response. J Clin Oncol. 1988;6:329–337.
   PubMed Web of Science ®Google Scholar
• Miller BJ, Cram P, Lynch CF, et al. Risk factors for metastatic disease at presentation with osteosarcoma: an analysis of the SEER database. J Bone Joint Surg Am. 2013;95(13):e89.
   PubMedGoogle Scholar
• Longhi A, Fabbri N, Donati D, et al. Neoadjuvant chemotherapy for patients with synchronous multifocal osteosarcoma: results in eleven cases. J Chemother. 2001;13:324–330.
   PubMed Web of Science ®Google Scholar
• Harris MB, Geiser P, Goorin AM, et al. Treatment of metastatic osteosarcoma at diagnosis: a pediatric oncology group study. J Clin Oncol. 1998;16:3641–3648.
   PubMed Web of Science ®Google Scholar
• Marina NM, Pratt CB, Rao BN, et al. Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis. Cancer. 1992;70:2722–2727.
   PubMed Web of Science ®Google Scholar
• Bacci G, Briccoli A, Mercuri M, et al. Osteosarcoma of the extremities with synchronous lung metastases: long-term results in 44 patients treated with neoadjuvant chemotherapy. J Chemother. 1998;10(1):69–76.
   PubMed Web of Science ®Google Scholar
• Meyers P, Haller G, Healey JH, et al. Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncol. 1993;11:449–453.
   PubMed Web of Science ®Google Scholar
• Bacci G, Briccoli A, Rocca M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities with metastases at presentation: recent experience at the Rizzoli Institute in 57 patients treated with cisplatin, doxorubicin, and a high dose of methotrexate and ifosfamide. Ann Oncol. 2003;14:1126–1134.
   PubMed Web of Science ®Google Scholar
• Kager L, Zoubek A, Potschger U, et al. Primaty metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2003;21:2011–2018.
   PubMed Web of Science ®Google Scholar
• Voute PA, Souhami RL, Nooij M. A Phase II study of cisplatin, ifosfamide and doxorubicin, in inoperable primary, axial, skeletal and metastatic osteosarcoma: European osteosarcoma intergroup (EOI). Ann Oncol. 1999;10:1211–1218.
   PubMed Web of Science ®Google Scholar
• Wuisman P. Enneking WF: prognosis for patients who have osteosarcoma with skip metastasis. J Bone Jont Surg Am. 1990;72:60–68.
   PubMed Web of Science ®Google Scholar
• Mialou V, Philip T, Kalifa C, et al. Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome. The French pediatric experience. Cancer. 2005;104:1100–1109.
   PubMed Web of Science ®Google Scholar
• Nataraj V, Rastogi S, Khan SA, et al. Prognosticating metastatic osteosarcoma treated with uniform chemotherapy protocol without high dose methotrexate and delayed metastasectomy: a single center experience of 102 patients. Clin Transl Oncol. 2016. doi:10.1007/s12094-015-1467-8.
   PubMedGoogle Scholar
• Salah S, Toubasi S. Factors predicting survival following complete surgical remission of pulmonary metastasis in osteosarcoma. Mole Clin Oncol. 2015;3:157–162.
   PubMedGoogle Scholar
• Briccoli A, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities metastatic to the lung: long-term results in 323 patients treated combining surgery and chemotherapy, 1985-2005. Surg Oncol. 2010;19:193–199.
   PubMed Web of Science ®Google Scholar
• Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma. Pharmacol Ther. 2013;137(1):89–99.
   PubMed Web of Science ®Google Scholar
• Hattinger CM, Pasello M, Ferrari S, et al. Emerging drugs for high grade osteosarcoma. Expert Opin Emerg Drugs. 2010;15(4):615–634.
   PubMed Web of Science ®Google Scholar
• Longhi A, Ferrari C, De Polis M, et al. Primary bone osteosarcoma in the pediatric age: state of the art. Cancer Treat Rev. 2006;32(6):423–436.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Heller G, Healey J, et al. Chemotherapy for nonmetastatic osteogenic sarcoma. The memorial Sloan-Kettering experience. J Clin Oncol. 1992;10:5–15.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Gorlick R, Heller G, et al. Intensification of preoperative chemotherapy for osteogenic sarcoma. Results of the memorial Sloan-Kettering (T12) protocol. J Clin Oncol. 1988;16:2452–2458.
   Google Scholar
• Lewis IJ, Nooij MS, Whelan J, et al. Improvement in histological response but non in survival in osteosarcoma patients treated intensified chemotherapy. A randomized phase III trial of the European osteosarcoma intergroup. J Natl Cancer Inst. 2007;99:112–128.
   PubMed Web of Science ®Google Scholar
• Pakos EE, Nearchou AD, Grimer RJ, et al. Prognostic factors and outcome for osteosarcoma: an international collaboration. Eur J Cancer. 2009;45:2367–2375.
   PubMed Web of Science ®Google Scholar
• Fuchs N, Bielack SS, Epler D, et al. Long-term results of the co-operative German-Austrian-Swiss osteosarcoma study group’s protocol COSS-86 of the intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs. Ann Oncol. 1998;9:893–899.
   PubMed Web of Science ®Google Scholar
• Bacci G, Ferrari S, Tienghi A, et al. A comparison of methods loco-regional chemotherapy combined with systemic chemotherapy as neo-adjuvant treatment of osteosarcoma of the extremity. Eur J Surg Oncol. 2001;27:98–104.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Ruggieri P, Cefalo G, et al. Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1. J Clin Oncol. 2012;30(17):2112–2118.
   PubMed Web of Science ®Google Scholar
• Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res. 2009;152:339–353.
   PubMedGoogle Scholar
• Whelan J, Bielack SS, Marina N, et al. EURAMOS-1, an international randomized study for osteosarcoma: results from pre-randomization treatment. Ann Oncol. 2015;26(2):407–414.
   PubMed Web of Science ®Google Scholar
• Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, Doxorubicin, and Cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33(20):2279–2287.
   PubMed Web of Science ®Google Scholar
• Marti C, Kroner T, Remagen W, et al. High-dose ifosfamide in advanced osteosarcoma. Cancer Treat Rep. 1985;69:115–117.
   PubMedGoogle Scholar
• Miser JS, Kinsella TJ, Triche TJ, et al. Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J Clin Oncol. 1987;5:1191–1198.
   PubMed Web of Science ®Google Scholar
• Pratt CB, Douglass EC, Ectubanas EL, et al. Ifosfamide in pediatric malignant solid tumors. Cancer Chemother Pharmacol. 1989;24(suppl 1):S11–S12.
   PubMedGoogle Scholar
• Schwartzman E, Scopinaro M, Angueyra N. Phase II study of ifosfamide as single drug for relapsed pediatric patients. Cancer Chemother Pharmacol. 1989;24(suppl 1):S11–S12.
   Google Scholar
• Le Deley MC, Guinebreitiere JM, Gentet JC, et al. SFOP OS94: a randomized trial comparing pre-operative high-dose methotrexate plus etoposide and ifosfamide in osteosarcoma patients. Eur J Cancer. 2007;43:752–761.
   PubMed Web of Science ®Google Scholar
• Bacci G, Briccoli A, Ferrari S, et al. Osteogenic sarcoma of the extremity with detectable lung metastases at presentation. Results of treatment of 23 patients with chemotherapy followed by simultaneous resection of primary and metastatic lesions. Cancer. 1997;15:245–254.
   Google Scholar
• Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20(2):426–433.
   PubMed Web of Science ®Google Scholar
• Daw N, Billups CA, Rodriguez-Galindo C, et al. Metastatic Osteosarcoma: results of two consecutive therapeutic trials at St. Jude children’s research hospital. Cancer. 2006;106(2):403–411.
   PubMed Web of Science ®Google Scholar
• Boye K, Brach Del Prever A, Eriksson M, et al. High-dose chemotherapy with stem cell rescue in the primary treatment of metastatic and pelvic osteosarcoma: final results of the ISG/SSG II study. Pediatr Blood Cancer. 2014;61:840–845.
   PubMed Web of Science ®Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma. A report from the children’s oncology group. Cancer. 2009;115:5339–5348.
   PubMed Web of Science ®Google Scholar
• Seibel NL, Krailo M, Chen Z, et al. Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma. children’s cancer group (CCG) 7943. Cancer. 2007;109:1646–1653.
   PubMed Web of Science ®Google Scholar
• Song BS, Seo J, Kim DH, et al. Gemcitabine and docetaxel for the treatment of children and adolescents with recurrent or refractory osteosarcoma: Korea cancer center hospital experience. Pediatr Blood Cancer. 2014;61:1376–1381.
   PubMed Web of Science ®Google Scholar
• Janinis J, McTiernan A, Mitchell C, et al. A pilot study of short-course intensive multiagent chemotherapy in metastatic and axial skeletal osteosarcoma. Ann Oncol. 2002;13:1935–1944.
   PubMed Web of Science ®Google Scholar
• O’Day K, Gorlick R. Novel therapeutic agents for osteosarcoma. Exp Rev Anticancer Ther. 2009;9:511–523.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93–99.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Pearson M. Novel therapeutic approaches in pediatric and young adult sarcomas. Curr Oncol Rep. 2006;8:310–315.
   PubMedGoogle Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarocma: the addition of muramyl tripeptide to chemotherapy improves overall survival. A report from the children’s oncology group. J Clin Oncol. 2008;26:633–638.
   PubMed Web of Science ®Google Scholar
• Treasure T, Milosevic M, Fiorentino F, et al. Pulmonary metastasectomy: what is the practice and where is the evidence for effectiveness? Thorax. 2014;69:946–949.
   PubMed Web of Science ®Google Scholar
• Treasure T, Macbeth F. Is surgery warranted for oligometastatic disease? Thorac Surg Clin. 2016;26:79–90.
   PubMed Web of Science ®Google Scholar
• Mizuno T, Taniguchi T, Ishikawa Y, et al. Pulmonary metastasectomy for osteogenic and soft tissue sarcoma: who really benefits from surgical treatment? Eur J Cardiothorac Surg. 2013;43:795–799. doi:10.1093/ejcts/ezs419.
   PubMed Web of Science ®Google Scholar
• Harting MT, Blakely ML, Jaffe N, et al. Long-term survival after aggressive resection of pulmonary metastases among children and adolescents with osteosarcoma. J Pediatr Surg. 2006;41:194–199.
   PubMed Web of Science ®Google Scholar
• Pastorino U. History of the surgical management of pulmonary metastases and development of the international registry. Semin Thorac Cardiovasc Surg. 2002;14:18–28.
   PubMedGoogle Scholar
• Bacci G, Rocca M, Salone M, et al. High grade osteosarcoma of the extremities with lung metastases at presentation: treatment with neoadjuvant chemotherapy and simultaneous resection of primary and metastatic lesions. J Surg Oncol. 2008;98(6):415–420.
   PubMed Web of Science ®Google Scholar
• Pfannschmidt J, Egerer G, Bischof M, et al. Surgical intervention for pulmonary metastases. Dtsch Arztebl Int. 2012;109:645–651.
   PubMed Web of Science ®Google Scholar
• Huang YM, Hou CH, Hou SM, et al. The metastasectomy and timing of pulmonary metastases on the outcome of osteosarcoma patients. Clin Med Oncol. 2009;3:99–105.
   PubMedGoogle Scholar
• Daw NC, Chou AJ, Jaffe N, et al. Recurrent osteosarcoma with a single pulmonary metastasis: a multi-institutional review. Br J Cancer. 2015;112:278–282.
   PubMed Web of Science ®Google Scholar
• Fernandez-Pineda I, Daw NC, McCarville B, et al. Patients with osteosarcoma with a single pulmonary nodule on computed tomography: a single-institution experience. J Pediatr Surg. 2012;47:1250–1254.
   PubMed Web of Science ®Google Scholar
• Durkovic S, Scanagatta P. Muscle-sparing thoracotomy: a systematic literature review and the “AVE” classification. J Surg Surgical Res. 2015;1(3):035–044.
   Google Scholar
• Fell SC, DeCamp MM. Technical aspects of lobectomy. In: Tw S, LoCicero J, Reed CE, et al., editors. General thoracic surgery. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2009. p. 479–485.
   Google Scholar
• Rolle A, Pereszlenyi A, Koch R, et al. Is surgery for multiple lung metastases reasonable? A total of 328 consecutive patients with multiple-laser metastasectomies with a new 1318-nm Nd: YAGlaser. J Thorac Cardiovasc Surg. 2006;131(6):1236–1242.
   PubMed Web of Science ®Google Scholar
• Meazza C, Scanagatta P, Luksch R, et al. How far can we go with surgery in metastatic osteosarcoma patients? Med Oncol. 2015;32(9):223.
   PubMed Web of Science ®Google Scholar
• Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the cooperative osteosarcoma study group. J Clin Oncol. 2003;21(2):334–341.
   PubMed Web of Science ®Google Scholar
• Oertel S, Blattmann, Rieken S. Radiotherapy in the treatment of primary osteosarcoma: a single center experience. Tumori. 2010;96:582–588.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Wisemann GA, Dispenzieri A, et al. Hihg-dose samarium-153-EDTMP ethylene diamnine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol. 2002;20:189–196.
   PubMed Web of Science ®Google Scholar
• Machak GN, Tkachec SI, Solovyev YN, et al. Neoadjuvant chemotherapy and local radiotherapy for high-grade osteosarcoma of the extremities. Mayo Clin Proc. 2003;78:147–155.
   PubMed Web of Science ®Google Scholar
• Ciernik IF, Niemierko A, Harmon DC, et al. Proton-based radiotherapy for unresectable or incompletely resected osteosarcoma. Cancer. 2011;117(19):4522–4530.
   PubMed Web of Science ®Google Scholar
• Matsunobu A, Imai R, Kamada T, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118:4555–4563.
   PubMed Web of Science ®Google Scholar
• Akiyama T, Dass C, Choong PF. Novel therapeutic strategy for osteosarcoma targeting osteoclast differentiation, bone-resorbing activity, and apoptosis pathway. Mol Cancer Ther. 2008;7:3461–3469.
   PubMed Web of Science ®Google Scholar
• Labrinidis A, Hay S, Liapis V, et al. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin Cancer Res. 2009;14:3451–3461.
   Web of Science ®Google Scholar
• Wolfe TD, Pillai SPS, Hildreth BE III, et al. Effect of zoledronic acid and amputation on bone invasion and lung metastasis of canine osteosarcoma in nude mice. Clin Exp Metastasis. 2011;28:377–389.
   PubMed Web of Science ®Google Scholar
• Anderson PM, Wiseman GA, Erlandson L, et al. Gemcitabine radiosensitization after high-dose samarium for osteoblastic osteosarcoma. Clin Cancer Res. 2005;11(19):6895–90.
   PubMed Web of Science ®Google Scholar
• Lee JA, Paik EK, Seo J, et al. Radiotherapy and gemcitabine-docetaxel chemotherapy in children and adolescents with unresectable recurrent or refractory osteosarcoma. Jap J Clin Oncol. 2016;46(2):138–143.
   PubMed Web of Science ®Google Scholar
• Chen X, Baharmi A, Pappo A, et al. Recurrent somatic structural variations contribute to tumorogenesis in pediatric osteosarcoma. Cell Rep. 2014;7:104–112.
   PubMed Web of Science ®Google Scholar
• Kuijjer ML, Hogendoorn PC, Cleron-Jansen AM. Genome-wide analyses on high-grade osteosarcoma: making sense of a genomically most unstable tumor. Int J Cancer. 2013;133(11):2512–2521.
   PubMed Web of Science ®Google Scholar
• Khanna C, Fan TM, Gorlick R, et al. Towards a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res. 2014;20:4200–4209.
   PubMed Web of Science ®Google Scholar
• Kansara M, Teng MW, Smyth MJ, et al. Translational biology of osteosarcoma. Nat Rev Cancer. 2014;14(11):722–735.
   PubMed Web of Science ®Google Scholar
• Wan X, Mendoza A, Khanna C, et al. Rapamycin inhibits ezrin-mediated metastatic behaviour in a murine model of osteosarcoma. Cancer Research. 2005;65(6):2406–2411.
   PubMed Web of Science ®Google Scholar
• Houghton PJ, Morton CL, Kolb EA, et al. Initial testing (stage I) of the mTOR inhibitor rapamycin by the paediatric preclinical testing program. Pediatric Blood Cancer. 2008;504(4):799–805.
   Web of Science ®Google Scholar
• Chawla SP, Staddon AP, Baker LH, et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78–84.
   PubMed Web of Science ®Google Scholar
• Demetri GD, Chawla SP, Ray-Coquard I, et al. Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo in patients after benefit from prior chemotherapy. J Clin Oncol. 2013;31(19):2485–2492.
   PubMed Web of Science ®Google Scholar
• Moriceau G, Ory B, Mitrofan L, et al. Zoledronic acid potentiates mTOR inhibition and abolishes the resistance of osteosarcoma cells to RAD001 (Everolimus): pivotal role of the prenylation process. Cancer Res. 2010;70(24):10329–10339.
   PubMed Web of Science ®Google Scholar
• Abdeen A, Chou AJ, Healey JH, et al. Correlation between clinical outcome and growth factor pathway expression in osteogenic sarcoma with advanced bone and soft tissue sarcomas. Cancer. 2009;115(22):5243–5250.
   PubMed Web of Science ®Google Scholar
• Fleuren ED, Versleijen-Jonkers YM, Roeffen MH, et al. Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. Int J Cancer. 2014;135(12):2770–2782.
   PubMed Web of Science ®Google Scholar
• Keir ST, Morton CL, Wu J, et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59(3):586–588.
   PubMed Web of Science ®Google Scholar
• Safwat A, Boysen A, Lücke A, et al. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol. 2014;53(10):1451–1454.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Grignani G, Cavalloni G, et al. Sorafenib blocks tumour growth, angiogenesis and metastatic potential in preclinical models of osteosarcoma through a mechanism potentially involving the inhibition of ERK1/2, MCL-1 and ezrin pathways. Mol Cancer. 2009;8:118.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23(2):508–516.
   PubMed Web of Science ®Google Scholar
• Pignochino Y, Dell’Aglio C, Basiricò M, et al. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models. Clin Cancer Res. 2013;19(8):2117–2131.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98–107.
   PubMed Web of Science ®Google Scholar
• Guagnano V, Kauffmann A, Wohrle S, et al. FGFR genetic alterations predict for sensitività to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov. 2012;2(12):118–133.
   Web of Science ®Google Scholar
• Xu M, Xu CX, Bi WZ, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. 2013;57(1):111–115.
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Reynolds CP, et al. Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2013;60(8):1325–1332.
   PubMed Web of Science ®Google Scholar
• Kolb EA, Gorlick R, Billups CA, et al. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014;61(10):1816–1821.
   PubMed Web of Science ®Google Scholar
• Beristain AG, Narala SR, Di Grappa MA, et al. Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells. J Cell Sci. 2012;125(Pt 4):943–955.
   PubMed Web of Science ®Google Scholar
• Gorlick R, Janeway K, Lessnick S, et al. COG bone tumor committee. Children’s oncology group’s 2013 blueprint for research: bone tumors. Pediatr Blood Cancer. 2013;60(6):1009–1015.
   PubMed Web of Science ®Google Scholar
• Roth M, Linkowski M, Tarim J, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120(4):548–554.
   PubMed Web of Science ®Google Scholar
• Yang Y, Niu X, Zhang Q, et al. The efficacy of abraxane on osteosarcoma xenografts in nude mice and expression of secreted protein, acidic and rich in cysteine. Am J Med Sci. 2012;344(3):199–205.
   PubMed Web of Science ®Google Scholar
• Zhang L, Marrano P, Kumar S, et al. Nab-paclitaxel is an active drug in preclinical model of pediatric solid tumors. Clin Cancer Res. 2013;19(21):5972–5983.
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, et al. Targeting programmed cell death ligand 1 in osteosarcoma: an auto-commentary on therapeutic potential. Oncoimmunology. 2014;3(8):e954467.
   PubMed Web of Science ®Google Scholar
• Zheng W, Xiao H, Liu H, et al. Expression of programmed death 1 is correlated with progression of osteosarcoma. Apmis. 2015;123(2):102–107.
   PubMed Web of Science ®Google Scholar
• Lussier DM, O’Neill L, Nieves LM, et al. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J Immunother. 2015;38(3):96–106.
   PubMed Web of Science ®Google Scholar